HK1072002A1 - Platinum derivative pharmaceutical formulations - Google Patents

Platinum derivative pharmaceutical formulations

Info

Publication number
HK1072002A1
HK1072002A1 HK05104822.1A HK05104822A HK1072002A1 HK 1072002 A1 HK1072002 A1 HK 1072002A1 HK 05104822 A HK05104822 A HK 05104822A HK 1072002 A1 HK1072002 A1 HK 1072002A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulations
platinum derivative
derivative pharmaceutical
platinum
formulations
Prior art date
Application number
HK05104822.1A
Other languages
English (en)
Inventor
Sara Lauria
Alessandro Martini
Cristina Ciocca
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21744006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1072002(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HK1072002A1 publication Critical patent/HK1072002A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK05104822.1A 2001-12-06 2005-06-08 Platinum derivative pharmaceutical formulations HK1072002A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/010,122 US6476068B1 (en) 2001-12-06 2001-12-06 Platinum derivative pharmaceutical formulations
PCT/EP2002/013146 WO2003047587A1 (en) 2001-12-06 2002-11-22 Platinum derivative pharmaceutical formulations

Publications (1)

Publication Number Publication Date
HK1072002A1 true HK1072002A1 (en) 2005-08-12

Family

ID=21744006

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104822.1A HK1072002A1 (en) 2001-12-06 2005-06-08 Platinum derivative pharmaceutical formulations

Country Status (42)

Country Link
US (3) US6476068B1 (bs)
EP (1) EP1453517B1 (bs)
JP (1) JP2005515202A (bs)
KR (1) KR100941210B1 (bs)
CN (1) CN100540006C (bs)
AP (1) AP1760A (bs)
AR (1) AR037629A1 (bs)
AT (1) ATE317260T1 (bs)
AU (1) AU2002352105B2 (bs)
BR (1) BR0214757A (bs)
CA (1) CA2468916C (bs)
CO (1) CO5580776A2 (bs)
CR (1) CR7362A (bs)
CY (1) CY1105608T1 (bs)
DE (1) DE60209145T2 (bs)
DK (1) DK1453517T3 (bs)
EA (1) EA008090B1 (bs)
EC (1) ECSP045140A (bs)
ES (1) ES2258661T3 (bs)
GE (1) GEP20063895B (bs)
HK (1) HK1072002A1 (bs)
HR (1) HRP20040514A2 (bs)
HU (1) HUP0402217A3 (bs)
IL (2) IL162348A0 (bs)
IS (1) IS2580B (bs)
MA (1) MA27153A1 (bs)
ME (1) MEP10408A (bs)
MX (1) MXPA04005423A (bs)
MY (1) MY134422A (bs)
NO (1) NO330159B1 (bs)
NZ (1) NZ533383A (bs)
OA (1) OA12739A (bs)
PL (1) PL206755B1 (bs)
PT (1) PT1453517E (bs)
RO (1) RO121509B1 (bs)
RS (1) RS50360B (bs)
SI (1) SI21493A (bs)
TN (1) TNSN04104A1 (bs)
TW (1) TW200409640A (bs)
UA (1) UA77728C2 (bs)
WO (1) WO2003047587A1 (bs)
ZA (1) ZA200404525B (bs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186172A1 (en) * 2001-07-02 2004-09-23 Houssam Ibrahim Oxaliplatin active substance with a very low content of oxalic acid
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
DE10314377A1 (de) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
CA2537170A1 (en) * 2003-08-28 2005-03-10 Mayne Pharma Pty Ltd Acid containing oxaliplatin formulations
GB2441445B (en) * 2003-08-28 2008-04-23 Mayne Pharma Ltd Acid containing oxaliplatin formulation
AU2004288709B2 (en) * 2003-11-07 2011-01-06 Novartis Vaccines And Diagnostics, Inc. Methods for synthesizing quinolinone compounds
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
CA2569739C (en) * 2004-06-09 2011-11-29 Katsuhisa Koizumi Antitumor effect potentiator, antitumor preparation, and method for treating cancer
WO2006023154A1 (en) * 2004-07-12 2006-03-02 Sicor, Inc. Cis-diiodo- (trans-l-1,2-cyclohexanediamine) platinum (ii) complex and processes for preparing high purity oxaliplatin
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
DE102004063764A1 (de) * 2004-12-29 2006-07-13 Hexal Ag Kunststoff-Flasche für Oxaliplatin
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
DE602005014393D1 (de) * 2005-03-28 2009-06-18 Dabur Pharma Ltd Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln
AU2006247803B2 (en) * 2005-05-13 2011-12-22 Novartis Ag Methods for treating drug resistant cancer
DE102005038347A1 (de) * 2005-08-11 2007-02-15 Hexal Ag Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (en) * 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
AU2006320591B2 (en) * 2005-11-29 2010-06-03 Novartis Ag Formulations of quinolinones
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
EP2152239A1 (en) 2007-11-12 2010-02-17 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
JP5579083B2 (ja) * 2008-02-29 2014-08-27 イーグル・ファーマシューティカルズ・インコーポレーテッド そのまま使用できるトポテカン溶液
WO2010056847A2 (en) * 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
MX348668B (es) * 2009-09-21 2017-06-23 J W Pharmaceutical Corp * Nanopartículas de oxaliplatin y método para prepararlas.
WO2012006101A2 (en) 2010-06-28 2012-01-12 The General Hospital Corporation Blood substitutes and uses thereof
CN102274171A (zh) * 2011-08-04 2011-12-14 上海希迪制药有限公司 一种奥沙利铂注射剂
JP2015524411A (ja) 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． エポキシケトン系プロテアソーム阻害剤のリポソーム組成物
JP5929607B2 (ja) * 2012-08-06 2016-06-08 ニプロ株式会社 オキサリプラチン製剤
CN102885765B (zh) * 2012-10-25 2013-11-06 哈药集团生物工程有限公司 一种盐酸伊立替康注射液及其制备方法
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
MX2018009670A (es) 2016-02-09 2019-09-04 Sun Pharmaceutical Ind Ltd Sistema de perfusion.
EP3538546A1 (en) 2016-11-14 2019-09-18 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
EP3737363A4 (en) 2018-01-12 2021-10-20 Metimedi Pharmaceuticals Co., Ltd METHODS OF TREATMENT OF CHRONIC INFLAMMATORY DISEASES
KR101998246B1 (ko) 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5041578A (en) * 1988-11-22 1991-08-20 Board Of Regents, The University Of Texas System Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
EP1393729A3 (en) 1991-11-15 2004-03-17 Smithkline Beecham Corporation Combination chemotherapy involving topotecan and a platinum coordination compound
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JPH06287021A (ja) 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
WO1994012193A1 (fr) 1992-11-24 1994-06-09 Debiopharm S.A. Combinaison de cisplatine avec l'oxaliplatine
AU5612694A (en) * 1992-11-27 1994-06-22 Napro Biotherapeutics, Inc. Injectable composition
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
US5716988A (en) 1994-08-08 1998-02-10 Debiopharm S.A. Pharmaceutically stable preparation of oxaliplatinum
ES2206478T3 (es) 1994-11-11 2004-05-16 Debiopharm S.A. Composiciones carcinostaticas que contienen cis-oxaliplatino y otra u otras sustancias carcinostaticas compatibles.
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
DE69627641T2 (de) * 1995-02-28 2004-02-05 Kidani, Yoshinori, Fujisawa Platin(iv)-komplexe, verfahren zu ihrer herstellung und sie enthaltende carcinostatische mittel
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
EP0897389B1 (fr) * 1996-03-11 2002-07-03 Yoshinori Kidani Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
UA71540C2 (uk) 1997-02-05 2004-12-15 Фармація Енд Апджон Компані Спосіб одержання ліпідних комплексів або ліпосом водонерозчинного діаміноциклогексанкарбоксилату платини та фармацевтична композиція, що містить ліпідний комплекс або ліпосоми водонерозчинного діаміноциклогексанкарбоксилату платини
DK1014990T3 (da) 1997-03-07 2006-12-11 Sanofi Aventis Us Llc Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
ES2178474T3 (es) 1998-10-14 2002-12-16 Debiopharm Sa Acondicionamiento de una preparacion de oxaliplatino.
ES2206288T3 (es) 1999-08-30 2004-05-16 Debiopharm S.A. Preparacion farmaceutica estable de oxiliplatino para su administracion por via parenteral.
AU2001240001A1 (en) 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
SE0003026D0 (sv) * 2000-08-25 2000-08-25 Kerstin Sunnerheim Use for conifer sapling protection

Also Published As

Publication number Publication date
IS2580B (is) 2010-02-15
US20030109514A1 (en) 2003-06-12
DE60209145D1 (de) 2006-04-20
IL162348A0 (en) 2005-11-20
ZA200404525B (en) 2005-08-15
TW200409640A (en) 2004-06-16
RO121509B1 (ro) 2007-10-30
SI21493A (sl) 2004-12-31
AR037629A1 (es) 2004-11-17
UA77728C2 (en) 2007-01-15
DK1453517T3 (da) 2006-06-19
US20030109515A1 (en) 2003-06-12
TNSN04104A1 (fr) 2006-06-01
MXPA04005423A (es) 2004-10-11
KR20050058278A (ko) 2005-06-16
HUP0402217A3 (en) 2005-11-28
MEP10408A (en) 2011-02-10
PL206755B1 (pl) 2010-09-30
AU2002352105B2 (en) 2009-12-03
WO2003047587A1 (en) 2003-06-12
CR7362A (es) 2009-02-12
NZ533383A (en) 2007-02-23
CN1612737A (zh) 2005-05-04
ATE317260T1 (de) 2006-02-15
CA2468916C (en) 2009-01-20
AP2004003055A0 (en) 2004-06-30
BR0214757A (pt) 2004-09-14
NO20042842L (no) 2004-07-05
PL370254A1 (en) 2005-05-16
PT1453517E (pt) 2006-06-30
AP1760A (en) 2007-07-18
CN100540006C (zh) 2009-09-16
JP2005515202A (ja) 2005-05-26
CY1105608T1 (el) 2010-12-22
US6476068B1 (en) 2002-11-05
NO330159B1 (no) 2011-02-28
ECSP045140A (es) 2004-08-27
EP1453517B1 (en) 2006-02-08
KR100941210B1 (ko) 2010-02-10
MA27153A1 (fr) 2005-01-03
AU2002352105A1 (en) 2003-06-17
OA12739A (en) 2006-06-30
YU59704A (sh) 2006-08-17
HRP20040514A2 (en) 2004-10-31
DE60209145T2 (de) 2006-10-26
US6673805B2 (en) 2004-01-06
ES2258661T3 (es) 2006-09-01
EA008090B1 (ru) 2007-02-27
RS50360B (sr) 2009-11-10
EP1453517A1 (en) 2004-09-08
CO5580776A2 (es) 2005-11-30
CA2468916A1 (en) 2003-06-12
EA200400777A1 (ru) 2004-12-30
HUP0402217A2 (hu) 2005-01-28
GEP20063895B (en) 2006-08-10
IS7298A (is) 2004-06-03
IL162348A (en) 2010-11-30
MY134422A (en) 2007-12-31

Similar Documents

Publication Publication Date Title
HK1072002A1 (en) Platinum derivative pharmaceutical formulations
GB0319041D0 (en) Pharmaceutical Formulations
GB0102342D0 (en) Pharmaceutical formulation
IL164519A0 (en) Pharmaceutical formulations
GB0118689D0 (en) Pharmaceutical formulation
PL366432A1 (en) Pharmaceutical formulation
EP1646355A4 (en) PHARMACEUTICAL FORMULATIONS
GB2392093B (en) Pharmaceutical formulations
GB0121715D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB0120701D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
GB0105560D0 (en) Pharmaceutical formulations
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
AU2002346457A8 (en) Pharmaceutical formulations comprising indolinone derivatives
GB0124455D0 (en) Pharmaceutical formulations
GB0014851D0 (en) Novel pharmaceutical formulation
GB0014892D0 (en) Novel pharmaceutical formulation
GB0014947D0 (en) Novel pharmaceutical formulation
GB0014883D0 (en) Novel pharmaceutical formulation
GB0104749D0 (en) Pharmaceutical formulation
GB0101966D0 (en) Pharmaceutical formulations
GB0118299D0 (en) Pharmaceutical formulations
GB0014869D0 (en) Novel pharmaceutical formulation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131122